Overview

A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Safety and efficacy of DE-114 ophthalmic solution will be evaluated in patients with allergic conjunctivitis, in an open-label, multicenter study.
Phase:
Phase 3
Details
Lead Sponsor:
Santen Pharmaceutical Co., Ltd.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions